Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease

Tamara Isakova*

*Corresponding author for this work

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

PURPOSE OF REVIEW: The aim is to review data on the epidemiology of fibroblast growth factor 23 (FGF23) and adverse clinical outcomes in chronic kidney disease (CKD) and introduce recent insights into the pathophysiology behind the observed relationships. RECENT FINDINGS: End-stage renal disease and cardiovascular disease are frequent events in patients with CKD, in whom cardiovascular disease is the leading cause of death. Elevated levels of FGF23, a phosphate and vitamin D-regulating hormone, have been associated with risks of end-stage renal disease, cardiovascular disease and mortality. FGF23 excess has also been linked with left-ventricular hypertrophy, and innovative translational experiments have recently established direct end-organ toxicity of FGF23, which induced left-ventricular hypertrophy in animals. SUMMARY: FGF23 is emerging as a novel risk factor in CKD. Future studies should determine whether interventions that lower FGF23 levels improve clinical outcomes in CKD.

Original languageEnglish (US)
Pages (from-to)334-340
Number of pages7
JournalCurrent opinion in nephrology and hypertension
Volume21
Issue number3
DOIs
StatePublished - May 2012

Keywords

  • cardiovascular disease
  • chronic kidney disease
  • fibroblast growth factor 23
  • mortality

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Fingerprint Dive into the research topics of 'Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease'. Together they form a unique fingerprint.

Cite this